Bancone G.Poe D.D.Gornsawun G.Htway P.P.Gilder M.E.Archasuksan L.Chotivanich K.McGready R.Nosten F.Mahidol University2024-03-132024-03-132024-01-01Wellcome Open Research Vol.7 (2024)https://repository.li.mahidol.ac.th/handle/20.500.14594/97564Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency represents a barrier to the full deployment of anti-malarial drugs for vivax malaria elimination and of first-line antibiotics. Lack of established reference ranges for G6PD activity in breast-fed infants puts them at risk of drug-induced haemolysis and restricts access to safe treatment of their mothers. Methods: The present work was undertaken to establish age-specific G6PD normal values using the gold standard spectrophotometric assay to support the future clinical use of tafenoquine in lactating women and safer antibiotic treatment in infants. Results: Spectrophotometric results collected at the Thai-Myanmar border from 78 healthy infants between the ages of 2 and 6 months showed a trend of decreased enzymatic activity with increasing age (which did not reach statistical significance when comparing 2–3 months old against 4–6 months old infants) and provided a reference normal value of 100% activity for infants 2–6 months old of 10.18IU/gHb. Conclusions: Normal reference G6PD activity in 2–6-month-old infants was approximately 140% of that observed in G6PD normal adults from the same population. Age specific G6PD activity thresholds should be used in paediatric populations to avoid drug-induced haemolysis.Biochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.12688/wellcomeopenres.18417.22-s2.0-851865900972398502X